Pediatric Clinical Trials
A listing of Pediatric medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 79 clinical trials
Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus
The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your bloodafter a single dose and measure how well it works to control your blood sugar level. We also want to make surethis study drug is safe for children and adolescents between …
- 0 views
- 19 Feb, 2024
- 1 location
A Prospective Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-Peds
The study medication for this research study is called LY900014. It is a type of mealtime insulin. The main reason for you to take part in this study is not to treat you for your diabetes but to help in answering the following research questions: •Does LY900014 help to lower …
- 0 views
- 19 Feb, 2024
- 1 location
Phase 2 Study of Imatinib in Children with Neurofibromatosis and Airway Tumors
The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy.
- 0 views
- 19 Feb, 2024
- 1 location
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
The purpose of this study is to compare the effects good and/or bad of carboplatin with cisplatin on people with standard risk germ cell tumors to find out which is better.
- 0 views
- 19 Feb, 2024
- 1 location
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
The purpose of this study is to find out if the drug, Cabozantinib, is safe and tolerable in pediatric patients with refractory and/or recurrent high grade gliomas (HGG) who have previously received radiation therapy. We are also looking to see if the drug has an effect on the rate at …
- 0 views
- 19 Feb, 2024
- 1 location
Observational Study for Pediatric Rheumatic Diseases: The CARRA Registry
The purpose of this study is to collect information regarding treatment plans and disease activity of current patients with pediatric onset rheumatic diseases, in the hopes that this information can help improve treatments and health outcomes for future patients.
- 0 views
- 19 Feb, 2024
- 1 location
Dissecting the Genetic Contributions to Fetal Alcohol Spectrum Disorders (DiG FASD)
The purpose of the “Dissecting the Genetic Contributions to Fetal Alcohol Spectrum Disorders” (DiG FASD) study is to understand how genetics affects FASD.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 3 2-part Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis Homozygous for F508del
This study is being done to learn more about the safety and effects of the combination of Lumacaftor (LUM) and Ivacaftor (IVA) in patients with Cystic Fibrosis between 1 to less than 2 years of age.
- 0 views
- 19 Feb, 2024
- 1 location
A phase 3 randomized double-blind placebo- and active-controlled parallel-arm trial to assess the efficacy safety and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen? when administered as a rescue therapy for severe hypoglycemia in children with T1DM treated with insulin
This study will compare medications used to treat low blood sugars (hypoglycemia).
- 0 views
- 19 Feb, 2024
- 1 location
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
- 0 views
- 19 Feb, 2024
- 1 location